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Inhibition of colony stimulating factor-1 receptor abrogates
microenvironment-mediated therapeutic resistance in gliomas
D Yan1, J Kowal2,3, L Akkari1,2,3, AJ Schuhmacher1, JT Huse4, BL West5 and JA Joyce1,2,3
Glioblastomas represent the most aggressive glioma grade and are associated with a poor patient prognosis. The current standard
of care, consisting of surgery, radiation and chemotherapy, only results in a median survival of 14 months, underscoring the
importance of developing effective new therapeutic strategies. Among the challenges in treating glioblastomas are primary
resistance and the rapid emergence of recurrent disease, which can result from tumor cell-intrinsic mechanisms in addition to
tumor microenvironment (TME)-mediated extrinsic resistance. Using a PDGF-B-driven proneural glioma mouse model, we assessed
a panel of tyrosine kinase inhibitors with different selectivity proﬁles. We found that PLX3397, an inhibitor of colony stimulating
factor-1 receptor (CSF-1R), blocks glioma progression, markedly suppresses tumor cell proliferation and reduces tumor grade. By
contrast, the multi-targeted tyrosine kinase inhibitors dovitinib and vatalanib, which directly target tumor cells, exert minimal
anti-tumoral effects in vivo, despite killing glioma cells in vitro, suggesting a TME-mediated resistance mechanism may be involved.
Interestingly, PLX3397 interferes with tumor-mediated education of macrophages and consequently restores the sensitivity of
glioma cells to tyrosine kinase inhibitors in vivo in preclinical combination trials. Our ﬁndings thus demonstrate that
microenvironmental alteration by CSF-1R blockade renders tumor cells more susceptible to receptor tyrosine kinase inhibition in a
preclinical glioblastoma model, which may have important translational relevance.
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INTRODUCTION
Glioblastomas are the most aggressive type of glioma and are
associated with a poor patient prognosis across all molecular
subtypes.1,2 Despite some progress in neurosurgery, radiotherapy
and chemotherapy treatment options, patient survival has
improved only marginally during the past three decades. Under
the current standard of care regimen, which consists of surgery,
radiation and chemotherapy with the alkylating agent temozolo-
mide, the median survival for patients diagnosed with glioblas-
toma is just 14.6 months.1 Therefore, this disease poses a
signiﬁcant challenge for contemporary healthcare, and novel
therapeutics are urgently required to address the unmet
medical needs.
The aggressiveness of glioblastoma is driven both by genetic
aberrations in glioma cells and alterations to the tumor micro-
environment (TME).3,4 Genetic changes such as PDGFRA ampliﬁca-
tion, TP53 loss, NF1 loss and EGFR mutation activate mitogenic
pathways, causing tumor cells to rapidly proliferate.5 Although
considerable effort has been directed towards inhibiting aber-
rantly activated signaling pathways in glioma cells,6 success
remains limited. A wide range of receptor tyrosine kinase (RTK)
inhibitors, predominantly targeting PDGFR and EGFR, has been
used to interfere with pro-proliferative and pro-invasive pathways
in gliomas. These inhibitors show variable preclinical efﬁcacy but
universally suffer from insufﬁcient clinical activity. For example,
the PDGFR inhibitor imatinib showed promising anti-tumor
activities in preclinical studies but failed to deliver signiﬁcant
survival improvement in patients with recurrent glioblastoma.7,8
The failure of these trials can likely be attributed to the fact that
multiple mechanisms are employed in glioblastoma to achieve
primary and acquired drug resistance. Several tumor cell-intrinsic
processes that mediate unresponsiveness to different treatments
have been identiﬁed to date, including activation of anti-apoptosis
pathways,9 bypass signaling,10 enrichment of glioma-initiating
cells11,12 and drug efﬂux machinery,13 among others. A glioma
cell-centric therapy thus needs to evade or overcome numerous
such processes in order to achieve a durable response, which is
challenging from a drug development perspective.
Therapeutic targeting of the glioma microenvironment, by
contrast, could be expected to represent a more tractable
strategy. Compared with tumor cells, non-neoplastic stromal and
immune cells are genomically stable, and are thus less prone to
the development of resistance and subsequent rapid clonal
evolution, a phenomenon linked to therapeutic failure.14 The
glioblastoma TME contains diverse populations of non-cancerous
cells, including resident microglia, recruited macrophages, imma-
ture myeloid cells, astrocytes, T cells, and endothelial cells, among
others.4,15,16 These cells are either inhibited in the immunosup-
pressive TME or actively engage in pro-tumorigenic activities.17
Notably, increasing evidence has demonstrated that tumor-
associated microglia and macrophages (TAMs) contribute to
glioma progression by enforcing immunosuppression and enhan-
cing proliferation, invasion and angiogenesis.4,18 Moreover, TAMs
can represent up to 30% of the glioblastoma mass,19,20 and TAM-
associated gene expression is signiﬁcantly associated with
reduced patient survival.21 These ﬁndings underscore the
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importance of TAM functions in glioblastoma, and provide a
strong rationale for therapeutically targeting this cell population.
Previously, we reported that inhibition of colony stimulating
factor-1 receptor (CSF-1R), using the small molecule BLZ945,
alters the functions of TAMs and thus blocks proneural
glioblastoma progression.22 These data indicate that re-
education of TAMs is a potent therapeutic strategy against
glioblastoma and should be further assessed in single-agent or
adjuvant/ neoadjuvant settings. However, questions remain as to
the relative beneﬁts of such a TME-targeting strategy versus
traditional tumor cell-targeted therapies. Therefore, in the
current study we directly compared these therapeutic options
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Figure 1. Preclinical tyrosine kinase inhibitor trials in the PDG model. (a) Tumor growth was monitored by schematic representation of trial
design. (b) Representative magnetic resonance images of treated gliomas on day − 1 and day 6, indicated by dashed lines. (c) Waterfall plot
showing a summary of tumor volume changes in all treatment arms: vehicle (n= 10), PLX3397 (n= 14), dovitinib (n= 8), vatalanib (n= 10), with
an initial tumor volume of o40 mm3 at the beginning of the trial. (d) Waterfall plot showing a summary of tumor volume changes in vehicle
(n= 2) and PLX3397 (n= 13) arms, with an initial tumor volume440 mm3. Vehicle large: gliomas with440 mm3 starting volume treated with
vehicle; PLX3397 Large: gliomas with 440 mm3 starting volume treated with PLX3397. (e) Percentage differences in tumor volume in all
treatment arms shown in Figures 1c and d. One-way analysis of variance with Sidak’s multiple comparisons test was used to calculate
statistical signiﬁcance. *Po0.05; **Po0.01; ****Po0.0001.
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as single agents and in combination to target both the tumor
and its supportive microenvironment.
RESULTS
CSF-1R inhibition blocks the progression of established proneural
gliomas
To directly compare the therapeutic efﬁcacy of CSF-1R inhibitors
with multi-targeted tyrosine kinase inhibitors, we selected
PLX3397, a potent CSF-1R and c-Kit inhibitor23 with demonstrated
clinical beneﬁt in synovial diffuse-type giant cell tumors,24 as well
as vatalanib and dovitinib, two inhibitors targeting multiple RTKs.
Vatalanib inhibits PDGFR-β, VEGFR1/2/3, c-Kit and CSF-1R to
varying degrees of efﬁcacy,25 and dovitinib inhibits Flt3, c-Kit,
FGFR1/3, VEGFR1/2/3, PDGFR-β and CSF-1R to different extents.26
For both drugs, substantially higher effective concentrations are
required for effective CSF-1R inhibition compared with their other
RTK targets. To conduct preclinical trials, we chose the immuno-
competent PDGF-B-driven glioma (PDG) genetically engineered
mouse model. In these mice, Nestin+ glioma-initiating cells
express the receptor for the replication-competent avian retro-
virus, thus allowing cell type-speciﬁc delivery of the oncogene
PDGF-B27 in an Ink4a/Arf-deﬁcient background. We previously
showed that CSF-1R expression is restricted to TAMs, and PDGFR-α
expression is glioma cell-speciﬁc.22 Further analysis of the TME by
immunostaining of PDG tumors herein revealed that a small
proportion of CD31+ endothelial cells express VEGFR2 (Supple-
mentary Figure S1A) and low levels of c-Kit (Supplementary
Figure S1B). In addition, a very small percentage of glioma cells
express low levels of c-Kit (Supplementary Figure S1B). Consistent
with the scarcity of evident c-Kit expression in glioma cells in vivo,
we did not detect Kit expression in PDGC23, a representative
glioma cell line derived from the PDG model22 nor the human
glioma cell line U-87MG (data not shown). There was also no
evident expression of c-Kit or VEGFR2 in CD68+ TAMs by
immunostaining (Supplementary Figures S1A and B).
To determine the effect of the RTK inhibitors on established
high-grade gliomas, mice with an initial tumor volume of
⩽ 40 mm3 were randomized into the vehicle arm or individual
inhibitor arms, such that animals with equivalent tumor volumes
were distributed comparably between the groups, and orally
dosed daily for 7 consecutive days. Tumor volume was monitored
by magnetic resonance imaging scans on day − 1 and day 6
(Figure 1a). On the basis of published studies, we selected the
dosages of inhibitors to satisfy three criteria: (i) equivalent molar
quantities of drugs should be administered to allow for fair
comparison of their efﬁcacy; (ii) therapeutic responses had been
documented in preclinical models of other tumor types using
similar dosages; and (iii) toxicity must be minimal.28–30 Pharma-
cokinetic analyses showed that all three compounds readily
entered the systemic circulation and were detectable in the brain
parenchyma 2 h following oral administration (Supplementary
Figure S1C). In the vehicle arm, all gliomas progressed, ranging
from 150 to 930% increase in tumor burden during the 7-day trial
(Figures 1b and c). Vatalanib or dovitinib treatment resulted in
only modest growth inhibition, with at least 50% of animals
showing a similar growth rate to vehicle-treated tumors
(Figures 1b and c). By contrast, PLX3397-treated gliomas showed
either tumor regression or considerably slower growth, ranging
from − 40 to +140% respectively (Figures 1b and c).
Given the relative efﬁcacy of PLX3397, we treated an
additional cohort of mice harboring an initial tumor volume of
440 mm3 (denoted as ‘PLX3397 Large’) with PLX3397. Tumor
volume-matching with a vehicle cohort of an equal size was not
feasible, because most vehicle-treated mice would not survive
the 7-day trial period due to the greater starting tumor burden,
compared to the trial described above. The vehicle-treated mice
(440 mm3 initial tumor volume) that did survive had appreci-
able tumor growth, ranging from 150 to 270%, whereas
PLX3397-treated mice showed either evident tumor regression
or halted tumor growth, ranging from − 30 to +6% (Figure 1d).
Statistical analysis of all groups (from Figure 1c) revealed that
PLX3397 decreased glioma growth by 97.5% compared to the
vehicle group (Figure 1e; Po0.0001). By comparison, vatalanib
and dovitinib reduced growth by 45.6 and 55.6%, respectively
(Figure 1e), highlighting the superior preclinical efﬁcacy of
PLX3397 in proneural gliomas.
The minimal efﬁcacy of vatalanib and dovitinib raised the
question as to whether these drugs indeed inhibited the intended
molecular targets. Therefore, we analyzed protein fractions from
treated whole tumors by immunoblotting for phosphorylated (p)
CSF-1R and PDGFR-α. When adjusted to total receptor levels,
PLX3397 potently inhibited CSF-1R phosphorylation, whereas
vatalanib and dovitinib exerted modest effects (Supplementary
Figure S1D). PDGFR-α phosphorylation was effectively inhibited by
both vatalanib and dovitinib (Supplementary Figure S1D), while
the effect of PLX3397 on PDGFR-α phosphorylation could not be
assessed due to very low numbers of PDGFR-α-positive tumor cells
in the efﬁciently debulked gliomas (Supplementary Figure S1D,
lower panels). These data demonstrate that all three inhibitors
efﬁciently act on their molecular targets in vivo. Of note, while
PLX3397 has reported afﬁnity to c-Kit, given that c-Kit expression
was observed in only some endothelial cells, a very small number
of glioma cells, and undetectable on TAMs (Supplementary
Figure S1B, and data not shown), we consider it unlikely that
c-Kit inhibition accounts for the robust anti-glioma activity of
PLX3397 in vivo in the animal model used here.
To examine the effect of the inhibitors directly on target cells,
we explored the dose–response relationship of individual
inhibitors using the murine PDGC23 glioma cell line, the human
U-87MG glioma cell line, mouse primary bone marrow-derived
macrophages (BMDMs) and human monocyte-derived macro-
phages (MDMs). PLX3397 had no effect on the survival of murine
glioma cells, whereas vatalanib and dovitinib reduced cell viability
at micromolar concentrations (Supplementary Figure S2A). On the
other hand, human U87 cells were killed by dovitinib, were
relatively insensitive to vatalanib, and not signiﬁcantly affected by
PLX3397 (Supplementary Figure S2A). In murine glioma cells, this
inhibitory effect appears to depend on PDGFR signaling, as
addition of PDGF-BB markedly increased the cellular IC50 in
PDGC23 cells (Supplementary Figure S2B). In murine BMDMs and
human MDMs, PLX3397 efﬁciently decreased cell viability, while
approximately 10-fold higher concentrations were required for
vatalanib and dovitinib to achieve similar effects (Supplementary
Figure S2C). This difference is also evident by immunoblotting
analysis where PLX3397, but neither vatalanib nor dovitinib,
successfully abolished CSF-1R phosphorylation at nanomolar
concentrations (Supplementary Figures S3A and B).
Changes in glioma cell viability can be caused by altered cell
cycle status, cell death or a combination of both. Cell cycle analysis
of dovitinib-treated PDGC23 glioma cells in culture revealed a
prominent G2-arrested subpopulation that was rapidly induced by
the inhibitor and persisted throughout the experimental time
course (Supplementary Figures S4A and E). Dovitinib progressively
elevated cell death, killing up to 55% of cells at the assay end
point (Supplementary Figure S4B; Po0.0001). Vatalanib dimin-
ished the S-phase subpopulation without inducing G2 arrest
(Supplementary Figures S4C and F), and killed ~ 35% of cells at the
cellular IC50 (Supplementary Figure S4D; Po0.0001). These data
suggest that both vatalanib and dovitinib regulate glioma cell
cycle and cell death, and dovitinib is a more potent anti-
proliferation agent in vitro.
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PLX3397 alters malignant features of gliomas
To investigate how the RTK inhibitors differentially altered glioma
progression in vivo, we analyzed tumors after the 7-day trial.
Histological analysis revealed that PLX3397 elicited substantial
tumor debulking, as indicated by a decrease in intratumoral nuclear
density, whereas vatalanib and dovitinib largely failed to do so
(Figure 2a). Histological blinded grading based on the 2007 WHO
classiﬁcation system showed that PLX3397 treatment resulted
mostly in lesions with grade II morphology (90%), with grade III
morphology in the remaining 10%. Grade IV histopathological
features were not apparent in this group, in contrast to the vehicle-
treated animals in which all lesions scored as grade IV glioblastoma
(Supplementary Figure S5A; Po0.0001). By comparison, vatalanib
had no effect on glioma grade relative to the vehicle group, and
dovitinib treatment resulted in an equivalent distribution of grade
IV and grade III gliomas (Supplementary Figure S5A).
We next assessed additional tumorigenic processes including
glioma cell proliferation, apoptosis, and the intratumoral
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Figure 2. Alterations of malignant features and TAM gene expression in treated gliomas. (a) Representative hematoxylin and eosin images of
treated tumors from the treatment groups shown in Figures 1c and d. Scale bar, 50 μm. (b) Quantiﬁcation of proliferating tumor cells (Olig2+
BrdU+) in all treatment arms. (c) Quantiﬁcation of the ratio of proliferating tumor cells to apoptotic cells within treated gliomas.
(d) Quantiﬁcation of CD68+ TAM density in all treatment arms. (e) MTT assay showing cell viability of BMDMs treated with GCM, PLX3397
(60 nM, based on estimated IC50 from dose–response studies in Supplementary Figure 2C), or a combination of both. Population doubling was
calculated using absorbance values (A595-A750) and time 0 values as normalization factors, n= 3 independent experiments. (f) Quantiﬁcation of
mRNA expression of M2-like genes, including Adm, Arg1, Mrc1, F13a1, Il10, Cd163, Stab1, Chil3, Irf4 and Ccl22, in treated gliomas, n= 3 tumors.
One-way analysis of variance with Sidak’s multiple comparisons test was used to calculate statistical signiﬁcance. *Po0.05; **Po0.01;
***Po0.001; ****Po0.0001; n.s. not signiﬁcant. For b, c, and d, each point represents a different tumor.
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microvasculature. In accordance with the histological changes,
PLX3397 dramatically decreased the proportion of Olig2+ glioma
cells to 20% of total cells, as compared to 80% in vehicle-treated
gliomas (Supplementary Figure S5; Po0.0001). We also pulse-
labeled proliferating glioma cells with BrdU in vivo, and observed
that the percentage of proliferating Olig2+ cells was markedly
reduced by 88.9% following PLX3397 treatment compared to the
vehicle group (Figure 2b and Supplementary Figure S5B;
Po0.0001). By contrast, neither vatalanib nor dovitinib changed
the percentage of total Olig2+ cells or actively proliferating glioma
cells in vivo (Figure 2b and Supplementary Figure S5). Quantiﬁca-
tion of apoptotic cells using cleaved caspase 3 (CC3) staining
showed a signiﬁcant increase in PLX3397-treated gliomas
(Supplementary Figure S5D; Po0.0001). As a result, PLX3397
signiﬁcantly decreased the tumor cell proliferation-to-apoptosis
ratio (Figure 2c; Po0.001). We also observed a modest decrease in
the proliferation-to-apoptosis ratio in dovitinib-treated gliomas,
which was mainly driven by a slight increase in apoptosis
(Figure 2c and Supplementary Figure S5D). To quantify potential
changes in the microvasculature, blood vessels were stained using
an anti-CD31 antibody. We did not observe signiﬁcant differences
in microvascular density across the treatment groups (Supple-
mentary Figure S5), but there was a signiﬁcant reduction in vessel
length in the dovitinib-treated group compared with the vehicle
group (Supplementary Figure S5G; Po0.05). Dovitinib can bind to
VEGFR, FGFR and PDGFR, all of which are associated with
angiogenesis and vessel maintenance, and thus the decreased
vessel length could be attributed to blockade of one or more of
these pathways. Together, these ﬁndings indicate the enhanced
biological efﬁcacy of a CSF-1R inhibition strategy compared to
other RTK targets in vivo.
PLX3397 induces gene expression changes in TAMs
In the context of CSF-1R blockade using a chemically distinct small
molecule inhibitor, BLZ945,22 we previously reported that TAMs
survive (due to the presence of survival factors including GM-CSF
and IFNγ in the proneural glioma microenvironment) but are ‘re-
educated’, concomitant with reduced expression of M2-like
macrophage genes. Similarly, we ﬁnd here that PLX3397-
mediated CSF-1R inactivation did not lead to a decrease in TAM
density compared to vehicle-treated gliomas (Figure 2d and
Supplementary Figure S6A, top row). Microglia in the adjacent
normal brain, however, were almost fully depleted following
PLX3397 treatment as expected (Supplementary Figure S6A,
bottom row), indicating that the glioma microenvironment
speciﬁcally promotes TAM survival in the context of CSF-1R
blockade, as we have also demonstrated with an independent
small molecule inhibitor.22 Interestingly, TAM density was similarly
unchanged in vatalanib-treated and dovitinib-treated gliomas
compared to vehicle, while microglia depletion was observed in
the adjacent normal brain of these treatment groups (Figure 2d
and Supplementary Figure S6A).
To investigate whether the secretion of soluble factors within
the glioma microenvironment has a role in macrophage protec-
tion from RTK inhibitor-induced killing, we performed BMDM
viability assays in culture using glioma-conditioned media (GCM)
generated from the PDGC23 cell lines. Without GCM, BMDMs were
sensitive to all three RTK inhibitors and were efﬁciently killed
(Figure 2e and Supplementary Figure S6). Incubation with GCM,
however, enabled BMDMs to survive in the presence of the
individual inhibitors (Figure 2e and Supplementary Figure S6),
suggesting that protective factors secreted by glioma cells can
render TAMs resistant to RTK inhibitor-mediated cytocidal effects.
Indeed, we previously identiﬁed GM-CSF, IFN-γ and CXCL10 as
glioma cell-secreted factors that keep TAMs alive in the context of
BLZ945 treatment.22 It is possible that these same factors also
protect macrophages from killing induced by the different RTK
inhibitors assessed here, which will be an interesting point to
investigate in future studies.
The viable TAMs remaining after PLX3397 treatment may
nonetheless assume a different phenotype, even if these cells are
not depleted within the TME. To test this possibility, we analyzed
the expression of a gene panel associated with M2-like gene
polarization in macrophages/ microglia, using RNA extracted from
treated whole gliomas. Speciﬁcally, we quantiﬁed Adm, Arg1, Mrc1,
F13a1, Il10, Cd163, Stab1 and Chil3, several of which had been
successfully used to capture TAM-related expression changes in
whole gliomas previously.22 Indeed, PLX3397 led to depolarization
of TAMs from their original M2-like state, as indicated by
signiﬁcant downregulation of Adm (Po0.001), Arg1 (Po0.05),
F13a1 (Po0.01), Il10 (Po0.01) and Chil3 (Po0.05), compared
with the vehicle group (Figure 2f). We did not observe concurrent
upregulation of M1-like associated genes in PLX3397-treated
gliomas (Supplementary Figure S6D). By contrast, vatalanib and
dovitinib only downregulated Adm (Po0.0001) (Figure 2f),
indicating that TAMs in these treated tumors were largely
maintained in an M2-like state.
TAM depolarization can be accompanied by important changes
in cellular functions.22 To determine whether PLX3397 alters the
pro-proliferative function of educated macrophages, we per-
formed conditioned media culture experiments that mimic the
heterotypic interactions between tumor cells and macrophages.
BMDMs were stimulated with GCM in the presence or absence of
PLX3397 for 48 h without media change to generate ‘processed’
GCM (stimulated MΦ CM), which was then applied back on
PDGC23 cells in culture (Supplementary Figure S6E). Cell cycle
analysis showed that, in response to the factors secreted by
glioma cells, CM collected from these stimulated BMDMs
subsequently upregulated tumor cell proliferation in a paracrine
manner, compared to CM generated by naïve BMDMs (Supple-
mentary Figure S6F, Po0.0001). This positive feedback loop,
however, was nearly abolished when macrophage function was
altered by the addition of PLX3397 during the BMDM stimulation
phase (Supplementary Figure S6F, Po0.0001). Taken together,
our data indicate that PLX3397 efﬁciently impairs the pro-
tumorigenic functions of TAMs, which likely contributes to the
reduced tumor growth or regression observed in vivo.
Combination therapy with PLX3397 and dovitinib or vatalanib
enhances therapeutic efﬁcacy
Considering that PLX3397 depolarized TAMs in gliomas, we
hypothesized that such phenotypically altered TAMs may render
glioma cells more sensitive to vatalanib or dovitinib in vivo.
Therefore, we treated a cohort of mice (including gliomas
⩽ 40 mm3 and 440 mm3) with a combination of PLX3397 and
either vatalanib or dovitinib using the same preclinical trial design
as in the single-agent trials (Figure 1a). Analysis of individual
tumor volumes by waterfall plots showed that the combination
therapy regressed the majority of gliomas to a greater extent than
PLX3397 alone. By applying the RECIST criteria of 30% tumor
volume reduction, 58.8% of the PLX3397 and vatalanib group, and
76.5% of PLX3397 and dovitinib group surpassed this reduction,
compared to 3.7% of tumors in the PLX3397 alone group and
none of the tumors in the vatalanib or dovitinib monotherapy
groups (Figures 1c and 3a). Statistical analysis revealed that the
combination therapies signiﬁcantly reduced overall tumor volume,
and performed better than PLX3397 alone (Figure 3b).
The combination therapies elicited robust and consistent
debulking in all gliomas (Figure 4a), which was supported by
immunohistochemical analyses (Supplementary Figure S7A;
Po0.0001). Furthermore, combined treatments abolished tumor
cell proliferation while inducing apoptosis, resulting in generally
lower proliferation-to-apoptosis ratios compared with PLX3397
alone, though the difference was not statistically signiﬁcant
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(Figures 4b and c and Supplementary Figure S7B and C). However,
we observed some sporadic high-grade features, such as
pseudopalisading necrosis (data not shown), and a higher
microvascular density and vessel length in the PLX3397 plus
vatalanib group, though not the PLX3397 plus dovitinib group
(Supplementary Figure S7D–F). These data suggest that in the
PDG model of proneural glioblastoma, destruction of the
intratumoral vascular network is not required for achieving glioma
regression. In the single-agent setting, microvascular density and
vessel length were unchanged after 7 days of PLX3397 treatment.
By contrast, dovitinib alone signiﬁcantly decreased vessel length
without a pronounced anti-glioma activity. In the combination
therapy setting, PLX3397 plus vatalanib resulted in a signiﬁcant
increase in microvascular density and vessel length, despite a
potent anti-glioma effect. Collectively, these ﬁndings indicate an
apparent disconnect between tumor regression and vascular
alterations, at least as assessed in end-stage lesions. Nonetheless,
agents that are capable of inducing more extensive vascular
damage within gliomas may still add beneﬁt to a CSF-1R inhibitor
combination therapy.
TAM density modestly increased compared with vehicle-treated
gliomas (Figure 4d and Supplementary Figure S8A; Po0.05),
indicating that the therapeutic efﬁcacy was not achieved via TAM
depletion. Indeed, compared with PLX3397 monotherapy, we
found that combination therapies further downregulated M2-like
gene expression of Stab1, Irf4 and Ccl22 (Figure 4e), though
without inducing M1-like genes (Supplementary Figure S8B).
Taken together, our ﬁndings demonstrate that concurrent
targeting of glioma cells and TAMs in their local microenviron-
ment signiﬁcantly improves therapeutic efﬁcacy.
DISCUSSION
In this preclinical study, we demonstrate that treatment with the
CSF-1R inhibitor PLX3397 is sufﬁcient to block glioma progression
in a single-agent setting. Speciﬁcally, we observed that PLX3397
induces TAM depolarization from an M2-like state, which is similar
to our previous ﬁnding using the chemically distinct CSF-1R
inhibitor, BLZ945.22 Furthermore, we found that PLX3397 effec-
tively improves the efﬁcacy of the multi-targeted kinase inhibitors
vatalanib and dovitinib in vivo, resulting in pronounced glioma
regression following combination treatments.
Our ﬁndings underscore the utility of TAM plasticity as a
therapeutic target in the glioma microenvironment. As evidenced
by our results herein from single-agent preclinical trials, appro-
priately reprogrammed TAMs not only lose their pro-tumorigenic
functions but also actively exert anti-tumoral effects. Underlying
this phenotypic switch is the downregulation of a subset of genes
that are associated with the M2-like state of TAMs. Genes such as
Arg1, Il10 and Chil3 have been implicated in TAM M2 polarization
across multiple cancers.31 The phenotypic alteration of TAMs
consequently renders glioma cells more susceptible to pharma-
cological inhibition of mitogenic RTKs, which provides an
opportunity to maximize therapeutic outcomes via combination
therapies. Interestingly, we found that combination therapies
further downregulated M2-associated genes such as Mrc1, Stab1
and Ccl22. Thus, TAM reprogramming potentially represents a
more effective strategy than TAM depletion for treating proneural
glioblastomas.
The differences between the efﬁcacy of multi-targeted RTK
inhibitors in vitro versus treatment in vivo suggests that pro-
tumorigenic TAMs may blunt the effectiveness of these therapies
in glioblastoma. Our data show that both vatalanib and dovitinib
are capable of efﬁciently arresting glioma cell proliferation and
inducing cell death in a monoculture setting, thus indicating the
presence of a cell-extrinsic resistance mechanism in vivo. Because
TAMs have been shown to interfere with the efﬁcacy of
chemotherapy and radiotherapy (reviewed in De Palma et al.,32
Ruffell et al.,33), it would be of interest to determine whether TAMs
also exert such an effect against RTK inhibitors in other tumor
types. The demonstrated efﬁcacy of combination therapies herein
suggests that TAM reprogramming by CSF-1R inhibition can
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Figure 3. Combination therapy enhances anti-glioma efﬁcacy in the PDG model. (a) Waterfall plot showing tumor volume changes in the
combination therapy arms: PLX3397+vatalanib (n= 17) and PLX3397+dovitinib (n= 17), compared with vehicle-treated (n= 12) and PLX3397-
treated (n= 27) gliomas (shown in Figures 1c and d), with RECIST cutoff of 30% regression indicated by the dashed line. (b) Tumor volume
changes in gliomas receiving combination therapies. Kruskal–Wallis test with Dunn's multiple comparisons test was used to calculate
statistical signiﬁcance. *Po0.05; **Po0.01; ***Po0.001.
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overcome primary or intrinsic resistance to multi-targeted RTK
inhibitors in glioblastomas, and thus warrants reconsideration of
these inhibitors in glioblastoma treatment in a combinatorial
setting. Because PLX3397 and some multi-targeted inhibitors,
such as dovitinib, have advanced through phase I clinical trials in
recurrent glioblastoma patients,34,35 it would be timely to explore
whether such combination therapies can improve clinical out-
comes in patients with newly diagnosed or recurrent glioblas-
toma. In parallel, it will be important to determine whether
PLX3397 also provides therapeutic beneﬁts in non-proneural
glioblastoma, where multiple RTK inhibitors can potentially be
utilized to perturb oncogenic pathways.
MATERIALS AND METHODS
Generation of PDGF-B-driven murine gliomas
The Nestin-Tv-a Ink4a/Arf− /− mouse line has been described previously27 and
was generously provided by Dr Eric Holland. Brieﬂy, to initiate gliomas, mice at
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Figure 4. Alterations of malignant features and TAM gene expression in gliomas treated with combination therapy. (a) Representative
hematoxylin and eosin images of gliomas in the vehicle, PLX3397, PLX3397+vatalanib, and PLX3397+dovitinib arms. Scale bar, 50 μm.
(b) Quantiﬁcation of tumor cell proliferation (Olig2+ BrdU+). (c) Quantiﬁcation of the ratio of proliferating tumor cells to apoptotic cells within
gliomas. (d) Quantiﬁcation of CD68+ TAM density. Values in the single-agent groups are from Figures 2b-d for comparison purposes.
(e) Quantiﬁcation of mRNA expression of M2-like genes, including Adm, Arg1, Mrc1, F13a1, Il10, Cd163, Stab1, Chil3, Irf4 and Ccl22, in treated
gliomas, n= 3 tumors. One-way analysis of variance with Sidak’s multiple comparisons test was used to calculate statistical signiﬁcance.
*Po0.05; **Po0.01; ***Po0.001; ****Po0.0001; n.s. not signiﬁcant. For b, c and d each point represents a different tumor.
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5-6 weeks of age (males and females) were intracranially injected with DF1 cells
harboring the replication-competent avian retrovirus-hPDGF-B-HA virus, using a
ﬁxed stereotactic apparatus (Stoelting, Wood Dale, IL, USA) under full
anesthesia with ketamine and xylazine. The injection was performed at a
depth of 2 mm into the right front cortex, using a coordinate that was 1.5 mm
lateral and 1 mm caudal from bregma, as previously described.22,36
Glioma regression trial
The size of cohorts was estimated based on our previous experience with
the genetically engineered PDG mouse model.22,36 All the experimental
animals enrolled were included in the tumor burden analyses, which were
conducted in a non-blinded manner. One day before treatment started
(4.5–5.5 weeks post-tumor initiation), PDG mice were scanned by magnetic
resonance imaging to measure tumor volume. Tumor-bearing mice with
gliomas ⩽ 40 mm3 were then randomized into different groups to receive
either vehicle or tyrosine kinase inhibitors. Mice with gliomas 440 mm3
were treated with PLX3397 or combination therapy, except for two mice
treated with vehicle. The vehicle for PLX3397 consists of 0.5% HPMC, 1%
PS80 and 5% DMSO. The vehicle for vatalanib and dovitinib is sterile water.
Mice were orally dosed by gavage once daily, and received PLX3397
(100 mg/kg), vatalanib (100 mg/kg) or dovitinib (120 mg/kg). For the
combination trials, mice were administered PLX3397 (100 mg/kg) and
either vatalanib (100 mg/kg) or dovitinib (120 mg/kg), 40 min apart. All
enrolled animals were scanned by magnetic resonance imaging on day 6,
and relative tumor volume changes were calculated compared to day − 1.
Unless otherwise indicated, mice were given the last dose of inhibitors 4 h
before sacriﬁce at the end of day 7. For each mouse whose tissue was
collected for immunohistochemical analyses, a dose of BrdU (100 mg/kg)
was injected intraperitoneally 2 h before sacriﬁce. All animal studies were
approved by the Institutional Animal Care and Use Committee of MSKCC.
Harvesting of mouse tissues
PDG mice were euthanized 7 days after treatment was initiated. Before
tissue harvest, each mouse was administered a lethal dose of avertin (2,2,2-
tribromoethanol, Sigma, St Louis, MO, USA), followed by transcardiac
perfusion with phosphate-buffered saline (PBS). To harvest tissues for
immunohistochemical analyses, each mouse was subsequently perfused
with 4% paraformaldehyde in PBS. Brains were ﬁxed in 4% paraformalde-
hyde overnight at 4 °C and transferred to 30% sucrose at 4 °C the next day.
All the other tissues were placed in 30% sucrose at 4 °C directly following
paraformaldehyde perfusion. After reaching equilibrium in sucrose, all
tissues were embedded in OCT compound (Tissue-Tek, Torrance, CA, USA).
To collect tissues for RNA and protein extraction, gliomas were carefully
dissected and snap frozen immediately following transcardial PBS perfusion.
Pharmacokinetic analysis
Non-tumor-bearing Nestin-Tv-a Ink4a/Arf− /− mice at 5 weeks of age were
orally administered a single dose of PLX3397 (100 mg/kg), vatalanib (100 mg/
kg) or dovitinib (120 mg/kg). After 2 h, mice were euthanized for plasma and
cerebellum collection. Samples were stored at −80 °C and sent to Integrated
Analytical Solutions (Berkeley, CA, USA) for quantitative analysis.
Histology and immunoﬂuorescence analyses
10 μm frozen sections were used for all analyses. For histological
assessment, hematoxylin and eosin staining was performed, and
histopathology was blindly scored by a neuropathologist (Dr Jason Huse)
based on the 2007 WHO criteria.37 For immunoﬂuorescence analyses, dried
frozen sections were rehydrated in PBS, permeabilized in 0.2% Triton
X-100, and blocked in 0.5% PNB (PerkinElmer, Waltham, MA, USA) for 1 h at
room temperature. Sections were then incubated with primary antibody
(for antibody information, see Supplementary Table 1) in 0.25% PNB at 4 °C
overnight, followed by PBS washes and incubation with ﬂuorophore-
conjugated secondary antibody (Life Technologies, Carlsbad, CA, USA) in
0.25% PNB for 1 h at room temperature. After repeated washes and
counterstaining with DAPI, sections were mounted with ProLong Gold
Antifade mounting media (Life Technologies). Stained tissue sections were
visualized under a Carl Zeiss (Thornwood, NY, USA) Axioimager Z1
microscope equipped with a TissueGnostics (Tarzana, CA; USA) scanning
stage or a Carl Zeiss Axioscan Z1 microscope equipped with Zen 2.3
software (Thornwood, NY, USA). Quantiﬁcation of intratumoral changes
was performed using TissueQuest and StrataQuest software (TissueGnos-
tics), as previously described.22
Generation of primary mouse bone marrow-derived macrophages
(BMDMs)
Wild-type C57BL/6 mice (6–8 weeks old) were euthanized by CO2. Hind
limbs were dissected, and bone marrow was ﬂushed out of the femur and
tibia using serum-free DMEM. Bone marrow-derived cells were allowed to
differentiate in DMEM with 10% fetal bovine serum and CSF-1 (10 ng/ml)
for 7 days, with media change and CSF-1 supplementation every other day.
BMDMs were then used in subsequent in vitro experiments.
Generation of primary human monocyte-derived macrophages
(MDMs)
Peripheral blood mononuclear cells were isolated by density gradient
isolation using Ficoll (GE Healthcare, Aurora, OH, USA) from fresh buffy coats
donated by consented healthy donors to the Swiss blood transfusion service.
Experiments were conducted in accordance to the guidelines of the Ethics
Commission of the University of Lausanne, Switzerland. Monocytes were
isolated by positive selection using magnetic beads targeting human CD14
(Miltenyi, Auburn, CA, USA). Cells were allowed to differentiate in DMEM
supplemented with 10% fetal bovine serum and 10 ng/ml CSF-1 (R&D
Systems) for 6 days, with media change and CSF-1 supplementation every
other day. MDMs were then used in subsequent in vitro experiments.
Cell culture
The generation and characterization of the PDGC23 glioma cell line has
been previously described.22 The U-87MG cell line was provided by Prof.
Monika Hegi’s lab (University of Lausanne, Switzerland). The cell lines were
grown in DMEM supplemented with 10 and 5% fetal bovine serum,
respectively. Both cell lines were routinely screened for mycoplasma.
Conditioned media experiments
To generate glioma-conditioned media (GCM), 5 × 106 PDGC23 cells were
incubated in 12 ml serum-free DMEM for 24 h. Harvested GCM was passed
through 0.22 μm ﬁlters to remove debris, and used to perform BMDM
protection assays in the presence of inhibitors. GCM was also used to
stimulate BMDMs (in the absence of CSF-1) for 48 h to produce ‘stimulated’
MΦ CM. Vehicle (DMSO) or PLX3397 (60 nM) was added during BMDM
stimulation to assess the effect of PLX3397.
Protein extraction and western blotting
To isolate protein from primary BMDMs and PDGC23 cells, lysis was
performed in NP-40 buffer containing protease and phosphatase inhibitors
(Thermo Scientiﬁc, Waltham, MA, USA). Protein extraction from MDMs and
U-87MG cells was performed with RIPA buffer (Sigma) containing protease
and phosphatase inhibitors (Thermo Scientiﬁc). To extract protein from
dissected gliomas, a pre-established biochemical fractionation protocol
was used.22,38 The resultant synaptosomal membrane fraction was lysed in
NP-40 buffer as described above. Extracted protein was resolved in 4-12%
Bis-Tris SDS-PAGE gels (Life Technologies), transferred to PVDF membrane
(Millipore, Billerica, MA, USA), and blocked with 5% non-fat milk.
Membranes were incubated overnight at 4 °C with primary antibodies
(Cell Signaling Technology, Danvers, MA, USA) against phosphorylated-
PDGFRα (Y762), phosphorylated-CSF-1R (Y723), total PDGFRα or total
CSF-1R (for antibody information, see Supplementary Table 1). Following
incubation with horseradish peroxidase-conjugated secondary antibody
(dilution 1:5000) for 1 h at room temperature, target protein was detected
using a chemiluminescence system (Thermo Scientiﬁc).
Cell cycle and cell death analysis
To determine the effect of tyrosine kinase inhibitors on glioma cells,
PDGC23 cells were treated with vatalanib (1, 5, 20 μM) or dovitinib (0.5, 1,
5 μM) for up to 48 h in serum-free DMEM. U-87MG cells were treated with
vatalanib (1, 10, 50 μM) or dovitinib (0.5, 1, 5 μM) in serum-free DMEM for
48 h. For conditioned media experiments (CM), PDGC23 cells were
incubated with stimulated MΦ CM for 48 h. Then cells were dissociated
by trypsinization, washed, and stained with LIVE/DEAD ﬁxable dye (near-IR,
Life Technologies) or Zombie NIR Viability kit (Biolegend, San Diego, CA,
USA). Cells were then permeabilized and stained with DAPI to allow for
simultaneous cell cycle analysis. After acquisition on a LSR II ﬂow cytometer
(BD, Franklin Lakes, NJ, USA), cell cycle stage and cell death were analyzed
using Flow Jo software (Ashland, OR, USA). Cell cycle was analyzed using
the Dean Jett Fox model.
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Cell viability assay
MTT assays were performed using the Cell Proliferation Kit I (Roche)
according to the manufacturer’s instructions. BMDMs and MDMs were
seeded at 7×103 cells/well and 20×103 cells/well respectively, incubated in
DMEM with 10% fetal bovine serum and CSF-1 (10 ng/ml) throughout the
experiments. PDGC23 and U-87MG cells were seeded at 4×103 cells/well and
10×103 cells/well respectively, incubated in serum-free DMEM until the end
point. All experimental assays were performed at the 48-h time point. For
U-87MG and MDM assays, values correspond to the difference between
absorbance at 560 and 690 nm, while for BMDMs and PDGC23 cell assays
absorbance was acquired at 595 and 750 nm.
RNA isolation, cDNA synthesis and qPCR
RNA was extracted using TRIzol (Life Technologies). For cDNA synthesis, the
Transcriptor First Strand cDNA Synthesis Kit (Roche) was used with 1 μg of
RNA. TaqMan probes (Life Technologies) for Ubc (Mm01201237_m1), Adm
(Mm00437438_g1), Arg1 (Mm00475988_m1), Mrc1 (Mm00485148_m1),
F13a1 (Mm00472334_m1), Il10 (Mm00439614_m1), Cd163
(Mm00474091_m1), Stab1 (Mm00460390_m1), Chil3 (Mm00657889_mH),
Irf4 (Mm00516431_m1), Ccl22 (Mm00436439_m1), Nos2 (Mm00440502_m1),
Ptgs2 (Mm00478374_m1), Il1b (Mm00434228_m1), Il12b (Mm00434174_m1),
Ccl2 (Mm00441242_m1), Ccl5 (Mm01302427_m1) and Cxcl10
(Mm00445235_m1) were used for qPCR. Assays were performed in triplicate
and relative expression was calculated after normalization to the house-
keeping gene Ubc for each sample.
Statistical analysis
Data are presented throughout as mean and± s.e.m, analyzed by the
indicated tests and a signiﬁcance cutoff of Po0.05. All statistical analyses
were completed in GraphPad Prism 6.0 or 7.0 (La Jolla, CA, USA).
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